KAMRAB-003: Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects
Study Details
Study Description
Brief Summary
The purpose of this study is to: 1. Evaluate the safety and tolerability of KamRAB in comparison with Human rabies immune globulin (HRIG) comparator product. 2. To assess whether KamRAB interferes with the development of self active antibodies when given simultaneously with active rabies vaccine, as compared to the HRIG comparator product, also given in conjunction with the active rabies vaccine.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
This is a prospective, randomized, double-blind, and single period non-inferiority and safety study conducted at a single study site. Subjects were randomized into the following two groups:
Group A: KamRAB (20 IU/kg by weight [bw]) intramuscular (IM), rabies vaccine (1.0 mL; ≥2.5 IU/mL) IM Group B: Human rabies immune globulin (HRIG) Comparator product (20 IU/kg bw) IM, rabies vaccine (1.0 mL; ≥2.5 IU/mL) IM The primary endpoint was a dichotomous (0-1) variable, defined by reaching an anti-rabies immunoglobulin G (IgG) concentration ≥0.5 IU/mL on Day 14. The primary hypothesis was that the proportion of KamRAB + vaccine recipients with anti-rabies concentration ≥0.5 IU/mL on Day 14 would not be less than the corresponding proportion of HRIG Comparator subjects by as much as 0.1.
The safety and tolerability of the study treatments was assessed based on: vital signs and physical examination findings, electrocardiogram (ECG), laboratory findings (hematology, clinical chemistry, and urinalysis) and the occurrence of adverse events (AEs) after drug administration
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: KamRAB KamRAB 20 IU/kg body weight via IM injection, once on Day 0 |
Drug: Active rabies vaccine (US-FDA approved)
A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
Other Names:
|
| Active Comparator: FDA approved HRIG product Comparator product: Intramuscular (IM) injection once on Day 0 in the same manner and at the same dosage as KamRAB. |
Drug: Active rabies vaccine (US-FDA approved)
A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL [Day 14]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Able and willing to sign an informed consent.
-
Healthy male or female subjects of 18 - 75 years of age inclusive who have not previously been immunized against rabies.
-
Ability to comply with completion of a home diary.
-
No previous exposure to Rabies epidemic, Rabies vaccine and/or Rabies Immune globulin.
-
No significant abnormalities in serum hematology, serum chemistry and serum immunogenic markers (C3, C4 and C50) according to the Principal Investigator's judgment.
-
No significant abnormalities in urinalysis according to the Principal Investigator's judgment.
-
No significant abnormalities in ECG per investigator judgment.
-
Non-pregnant, non-lactating female subjects, whose screening pregnancy test is negative and who are using contraceptive methods deemed reliable by the investigator, or who are more than 5 years post-menopausal or surgically sterilized.
-
Male subjects must be using at least one effective contraceptive method before study start and throughout the entire duration of the study.
Exclusion Criteria:
-
History or laboratory evidence of immunoglobulin A deficiency.
-
A history of previous administration of rabies vaccine or HRIG.
-
History of live virus vaccine administration, e.g., measles vaccine, within the last 3 months.
-
History of anaphylactic or anaphylactoid hypersensitivity reactions to chicken egg; history of mild allergic reactions to chicken egg, e.g., skin rash only, is not an exclusion criterion
-
History of hypersensitivity reaction to any of the following components of active rabies vaccine (US-FDA approved) e.g.: neomycin, bovine gelatin, trace amounts of chicken protein, chlortetracycline, and amphotericin B and in accordance with the product insert of the vaccine.
-
History of hypersensitivity reaction to any of the components in an equivalent active Rabies vaccine.
-
History of allergy to blood or blood products.
-
History of bleeding disorders.
-
Fever at the time of the start of the infusion. (Oral temperature >38ºC.)
-
Clinically significant intercurrent illnesses including: cardiac, hepatic, renal, endocrine, neurological, hematological, neoplastic, immunological, skeletal or other) that in the opinion of the investigator, could interfere with the safety, compliance or other aspects of this study.
-
Evidence of active systemic infection that required treatment with antibiotics within 2 weeks of the time of drug administration.
-
Evidence of uncontrolled hypertension (systolic blood pressure of >150 mm Hg, and/or diastolic blood pressure of >100 mm Hg).
-
Heart rate >120/min.
-
Weight > 93.75 kg
-
Pregnancy and/or lactation.
-
Woman of child-bearing potential not taking adequate contraception deemed reliable by the investigator.
-
All types of malignancies except for basal and squamous cell (scaly or plate-like) skin cancer or situ cervical carcinoma must be in remission for a minimum of 5 years., For non-melanoma skin cancers and carcinoma in-situ of the cervix may be enrolled if treated and cured at the time of screening.
-
Previous organ transplant recipient.
-
Evidence of ongoing infection with Hepatitis A, C, or B, or HIV 1/2.
-
Presence of psychiatric disorder, other mental disorder or any other medical disorder which might impair the subject's ability to give informed consent or to comply with the requirements of the study protocol.
-
Previous enrolment in this study.
-
Participation in another clinical trial within 30 days prior to baseline visit.
-
Evidence of alcohol abuse or history of alcohol abuse or illegal and/or legally prescribed drugs in the past 10 years.
-
History of life threatening allergy, anaphylactic reaction, or systemic response to human plasma derived products.
-
Known hypersensitivity to any of the ingredients or excipients of the study drugs.
-
Any other factor that, in the opinion of the investigator, would prevent the subject from complying with the requirements of the protocol.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Prism Research Inc | Saint Paul | Minnesota | United States | 55114 |
Sponsors and Collaborators
- Kamada, Ltd.
Investigators
- Principal Investigator: Mark Matson, M.D., Prism Research Inc
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- KAMRAB-003
Study Results
Participant Flow
| Recruitment Details | |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | KamRAB | FDA Approved Commercially Available HRIG Product |
|---|---|---|
| Arm/Group Description | KamRAB 20 IU/kg body weight via IM injection, once on Day 0 Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 | Comparator product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB. Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 |
| Period Title: Overall Study | ||
| STARTED | 59 | 59 |
| COMPLETED | 56 | 57 |
| NOT COMPLETED | 3 | 2 |
Baseline Characteristics
| Arm/Group Title | KamRAB | HRIG Comparator Product | Total |
|---|---|---|---|
| Arm/Group Description | KamRAB 20 IU/kg body weight via IM injection, once on Day 0 Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 | FDA Approved Commercially Available HRIG Product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB. Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 | Total of all reporting groups |
| Overall Participants | 59 | 59 | 118 |
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
43.3
(16.15)
|
46.3
(14.5)
|
44.8
(15.35)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
37
62.7%
|
38
64.4%
|
75
63.6%
|
| Male |
22
37.3%
|
21
35.6%
|
43
36.4%
|
| Race (NIH/OMB) (Count of Participants) | |||
| American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
| Asian |
1
1.7%
|
0
0%
|
1
0.8%
|
| Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
| Black or African American |
0
0%
|
4
6.8%
|
4
3.4%
|
| White |
57
96.6%
|
53
89.8%
|
110
93.2%
|
| More than one race |
0
0%
|
0
0%
|
0
0%
|
| Unknown or Not Reported |
1
1.7%
|
2
3.4%
|
3
2.5%
|
Outcome Measures
| Title | The Difference Between KamRAB and HRIG Comparator, in the Proportions of Subjects With Serum Anti-rabies IgG Antibody Concentration ≥ 0.5 IU/mL |
|---|---|
| Description | |
| Time Frame | Day 14 |
Outcome Measure Data
| Analysis Population Description |
|---|
| [Not Specified] |
| Arm/Group Title | KamRAB | HRIG Comparator Product |
|---|---|---|
| Arm/Group Description | KamRAB 20 IU/kg body weight via IM injection, once on Day 0 Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 | FDA Approved Commercially Available HRIG Product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB. Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 |
| Measure Participants | 56 | 58 |
| Count of Participants [Participants] |
55
93.2%
|
58
98.3%
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | KamRAB, HRIG Comparator Product |
|---|---|---|
| Comments | The null hypothesis was that Cp ≤ -0.1. | |
| Type of Statistical Test | Non-Inferiority or Equivalence (legacy) | |
| Comments | We will reject the null hypothesis at the one-sided 5% significance level, and conclude that Cp > -0.1, if the lower bound of an exact 90% binomial confidence interval (CI) exceeds0.1. A sample size of 53 in each group provides 80% power to reject the null hypothesis. | |
| Statistical Test of Hypothesis | p-Value | |
| Comments | ||
| Method | ||
| Comments | ||
| Method of Estimation | Estimation Parameter | Mean Difference (Net) |
| Estimated Value | -0.018 | |
| Confidence Interval |
(2-Sided) 90% -0.082 to 0.031 |
|
| Parameter Dispersion |
Type: Value: |
|
| Estimation Comments | ||
Adverse Events
| Time Frame | From signature of informed consent (ICF) to 185 days (post 8 half lives of product) | |||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | KamRAB | FDA Approved Commercially Available HRIG Product | ||
| Arm/Group Description | KamRAB 20 IU/kg body weight via IM injection, once on Day 0 Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 | Comparator product: IM injection once on Day 0 in the same manner and at the same dosage as KamRAB. Active rabies vaccine (US-FDA approved): A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 | ||
All Cause Mortality |
||||
| KamRAB | FDA Approved Commercially Available HRIG Product | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 0/59 (0%) | 0/59 (0%) | ||
Serious Adverse Events |
||||
| KamRAB | FDA Approved Commercially Available HRIG Product | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 1/59 (1.7%) | 0/59 (0%) | ||
| Neoplasms benign, malignant and unspecified (incl cysts and polyps) | ||||
| Intraductal proliferative breast lesion | 1/59 (1.7%) | 1 | 0/59 (0%) | 0 |
Other (Not Including Serious) Adverse Events |
||||
| KamRAB | FDA Approved Commercially Available HRIG Product | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 48/59 (81.4%) | 51/59 (86.4%) | ||
| Gastrointestinal disorders | ||||
| Nausea | 4/59 (6.8%) | 4 | 2/59 (3.4%) | 3 |
| Diarrhoea | 2/59 (3.4%) | 2 | 2/59 (3.4%) | 2 |
| General disorders | ||||
| Fatigue | 3/59 (5.1%) | 3 | 1/59 (1.7%) | 1 |
| Injection site pain | 29/59 (49.2%) | 59 | 43/59 (72.9%) | 43 |
| Injury, poisoning and procedural complications | ||||
| Laceration | 2/59 (3.4%) | 3 | 2/59 (3.4%) | 3 |
| Musculoskeletal and connective tissue disorders | ||||
| Myalgia | 8/59 (13.6%) | 8 | 6/59 (10.2%) | 6 |
| Pain in extremity | 2/59 (3.4%) | 2 | 3/59 (5.1%) | 3 |
| Arthralgia | 4/59 (6.8%) | 4 | 0/59 (0%) | 0 |
| Back pain | 2/59 (3.4%) | 2 | 2/59 (3.4%) | 2 |
| Nervous system disorders | ||||
| Headache | 8/59 (13.6%) | 8 | 9/59 (15.3%) | 10 |
| Dizziness | 3/59 (5.1%) | 3 | 2/59 (3.4%) | 3 |
| Presyncope | 4/59 (6.8%) | 4 | 1/59 (1.7%) | 1 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Upper respiratory tract infection | 8/59 (13.6%) | 9 | 8/59 (13.6%) | 11 |
| Skin and subcutaneous tissue disorders | ||||
| Ecchymosis | 3/59 (5.1%) | 3 | 1/59 (1.7%) | 1 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
agreement disclosure that restricts the right of the PI to discuss or publish trial results after the trial is completed
Results Point of Contact
| Name/Title | Eran Schenker, VP Medical Director |
|---|---|
| Organization | Kamada |
| Phone | +972-8-9406472 |
| Erans@kamada.com |
- KAMRAB-003